Intelligent thrombosis prevention

Develops a new preventive drug that normalizes the body’s own defence system against blood clots – to be used on the global market for the prevention of complications resulting from thrombosis-related cardiovascular diseases. The benefit of this new therapy compared to all current preventive antithrombotic therapy is expected to be an improved balance between blood clot prevention and side effects (bleedings).

Impact: More effective treatment creates opportunities to reduce the suffering of large groups of patients leading to significant health and economic benefits.

CEO: Sten R. Sörensen
GUV Contact: Klementina Österberg